80 related articles for article (PubMed ID: 12733734)
1. A longitudinal study of the effect of subcutaneous estrogen replacement on bone in young women with Turner's syndrome.
Khastgir G; Studd JW; Fox SW; Jones J; Alaghband-Zadeh J; Chow JW
J Bone Miner Res; 2003 May; 18(5):925-32. PubMed ID: 12733734
[TBL] [Abstract][Full Text] [Related]
2. Pregnancies in women with Turner's syndrome.
Hovatta O
Ann Med; 1999 Apr; 31(2):106-10. PubMed ID: 10344582
[TBL] [Abstract][Full Text] [Related]
3. Bone demineralization, biochemical indices of bone remodeling, and estrogen replacement therapy in adults with Turner's syndrome.
Stĕpán JJ; Musilová J; Pacovský V
J Bone Miner Res; 1989 Apr; 4(2):193-8. PubMed ID: 2786321
[TBL] [Abstract][Full Text] [Related]
4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
5. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
7. [Effect of hormone replacement therapy on lipid metabolism in patients with premature ovarian failure and Turner's syndrome].
Yahata T; Kurabayashi T; Kato R; Yamamoto Y; Fujimaki T; Yasuda M; Oda K; Yoshizawa H; Tanaka K
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Nov; 46(11):1197-204. PubMed ID: 7844437
[TBL] [Abstract][Full Text] [Related]
8. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
9. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
10. Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner's syndrome.
Han TS; Cadge B; Conway GS
Clin Endocrinol (Oxf); 2006 Nov; 65(5):643-7. PubMed ID: 17054467
[TBL] [Abstract][Full Text] [Related]
11. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
Ascott-Evans BH; Guanabens N; Kivinen S; Stuckey BG; Magaril CH; Vandormael K; Stych B; Melton ME
Arch Intern Med; 2003 Apr; 163(7):789-94. PubMed ID: 12695269
[TBL] [Abstract][Full Text] [Related]
12. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
13. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
16. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
17. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study.
Khastgir G; Studd J; Holland N; Alaghband-Zadeh J; Fox S; Chow J
J Clin Endocrinol Metab; 2001 Jan; 86(1):289-95. PubMed ID: 11232014
[TBL] [Abstract][Full Text] [Related]
18. Decreased bone mass despite long-term estrogen replacement therapy in young women with Turner's syndrome and previously normal bone density.
Lanes R; Gunczler P; Esaa S; Martinis R; Villaroel O; Weisinger JR
Fertil Steril; 1999 Nov; 72(5):896-9. PubMed ID: 10560996
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner's Syndrome.
Faienza MF; Brunetti G; Ventura A; Piacente L; Messina MF; De Luca F; Ciccarelli M; Oranger A; Mori G; Natale MP; Gigante M; Ranieri E; Gesualdo L; Colucci S; Cavallo L; Grano M
Bone; 2015 Dec; 81():228-236. PubMed ID: 26208797
[TBL] [Abstract][Full Text] [Related]
20. Effect of hormone replacement therapy on spinal bone mineral density and T lymphocyte subsets in premature ovarian failure and Turner's syndrome.
Kurabayashi T; Yasuda M; Fujimaki T; Yamamoto Y; Oda K; Tanaka K
Int J Gynaecol Obstet; 1993 Jul; 42(1):25-31. PubMed ID: 8103471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
